BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Novogen Limited (NVGN) Receives Nasdaq Notice


7/23/2010 11:57:36 AM

SYDNEY, AUSTRALIA--(Marketwire - July 23, 2010) -

Novogen Limited (ASX: NRT) (NASDAQ: NVGN) is listed on the Australian Stock Exchange and has an ADR program in place in the US through the Nasdaq Stock Market. An ADR for the Company represents a bundle of 5 ASX shares, therefore the bid price of an ADR on the NASDAQ is five times the ASX share bid price.

The Company received a letter from The Nasdaq Stock Market on July 19, 2010 notifying it that for the last 30 consecutive business days the bid price of the Company's common stock closed below the minimum US$1.00 per share requirement for continued inclusion on the Nasdaq Global Market under Nasdaq Rule 5450(a)(1). According to Nasdaq's letter, the Company will be afforded a grace period of 180 calendar days, or until January 18, 2011, to regain compliance in accordance with Nasdaq Rule 5810(c)(3)(A). In order to regain compliance, shares of the Company's common stock must maintain a minimum bid closing price of at least US$1.00 per share for a minimum of ten consecutive business days during the grace period.

The Company intends to actively monitor the bid price of its common stock between now and January 18, 2011.

This notification from The Nasdaq Stock Market has no bearing on the ASX listing.

About Novogen Limited

Novogen Limited is an Australian biotechnology company based in Sydney, Australia, that is developing a range of oncology therapeutics from its proprietary flavonoid synthetic chemistry technology platform. More information on the Novogen group of companies can be found at www.novogen.com.


FOR FURTHER INFORMATION:

Phillip Johnston
Chairman
Novogen Limited
TEL + 61 (02) 9878 0088
http://www.novogen.com

WHITECOAT Strategies
David Sheon
+ 1 202-422-6999



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES